Cvent Unveils 2018 List of Top 50 Meeting Hotels in Europe
Cvent, Inc., a market leader in meetings, events, and hospitality technology, today announced the results of its Top 50 Meeting Hotels in Europe . Due to increased group business demand, venues in Europe are ranked in a standalone list this year after previously being included in the Europe, Middle East, and Africa category. The list was compiled by analysing group booking activity through its Cvent Supplier Network, which sourced more than $14.7 billion and more than 40 million room nights in 2017, helping to support more than 715,000 events worldwide.
“With industry research showing the current global value of the MICE industry at $750+ billion and growing substantially, and Europe dominating with a market share of 42%*, there is huge potential for hotels across the region to capitalise on group business opportunities,” said Bharet Malhotra, Senior Vice President of Sales for Cvent’s Hospitality Cloud. “Based on these market trends, it made sense for us to provide a European-only list that would offer the industry what they are looking for: top European venues for their meetings and events.”
Europe List Highlights:
- Hilton took the top three spots for generating the most MICE business in Europe: Hilton Prague, Hilton London Metropole, The Double Tree by Hilton, Amsterdam Centraal Station in that order.
- Marriott, Hilton, and IHG (in that order) are the top three hotel chains represented on the Top 50 list.
Germany and Spain represent the largest selection of hotels on the
list with 12 and 10 in the Top 50 respectively including the following
chains and brands:
- Radisson Blu, Sheraton, NH Hotel Group, Renaissance, W Hotels, Melia, and AccorHotels
“I am truly proud to see Hilton Prague being recognized,” said Hilton Prague General Manager Michael Specking. “Hilton Prague is a fantastic contemporary venue of 800 bedrooms and 5,000 sq. meters of convention space in a fabulous downtown location, and it’s the team’s focus to consistently deliver high level of services to make our promise happen: ‘Your vision, our passion.’”
“We saw many large-scale renovations in the European market this year as venues vie for group business and look to attract the large number of international conferences hosted in the region,” said Chris McAndrews, Vice President of Marketing for Cvent’s Hospitality Cloud. “With such big changes and new entries making it into the Top 50 list this year, and an increasing number of hotels keen to invest to meet the requirements of the 21st century business traveller, it will be interesting to see this time next year who will take the top spots.”
Due to increased demand and buyer preferences, Cvent also announced it has expanded its list categories to include sub-lists which segment venues further based on commonly searched attributes including property type, conference space size, and region-specific locales. These lists will be announced over the coming weeks.
Top 10 Hotel Properties in Europe:
For the complete Top 50 table please see HERE
|2018 Rank||Hotel Name|
|2||Hilton London Metropole|
|3||DoubleTree by Hilton, Amsterdam Centraal Station|
|4||Hotel Arts Barcelona|
|5||Sheraton Frankfurt Airport Hotel & Conference Centre|
|6||Hilton Munich Park|
|7||Hilton Diagonal Mar Barcelona|
|8||Rome Marriott Park Hotel|
|9||Hilton London Paddington|
Cvent evaluated hotel properties that generated business through the Cvent Supplier Network from January 2017 through December 2017. The properties were ranked according to various criteria, including total requests for proposals (RFPs), awarded RFPs, total room nights, awarded room nights, major metropolitan area (MMA) market share, conversion rate, and the hotel's unique profile visits in the Cvent Supplier Network. The criteria are designed to provide the most accurate reflection of the top meeting hotels in the U.S., Europe, Middle East and Africa, and Asia Pacific regions.
*Allied Market Research, Jan 2018
About the Cvent Supplier Network
Featuring more than 255,000 hotels, resorts and special event venues, the Cvent Supplier Network is one of the world's largest and most accurate databases of detailed venue information. Cvent sourced more than $14.7 billion in meetings and events through its marketplace and more than 40 Million room nights in 2017. The CSN contains listings of hotels and other venues in more than 175 countries that can be searched and filtered based on approximately 200 meetings and events attributes. The Network is part of the Cvent Hospitality Cloud, which provides hotels, CVBs and other event venue owners, solutions to effectively generate qualified demand for meetings and events, manage that demand more efficiently, and measure group business performance.
For more information regarding the Cvent Supplier Network, visit www.cvent.com/venues.
Cvent, Inc. is a leading cloud-based enterprise event management company with more than 25,000 customers, 300,000 users, and 3,000 employees worldwide. Cvent offers software solutions to event planners for online event registration, venue selection, event management, mobile apps for events, email marketing, and web surveys. Cvent provides hoteliers with an integrated platform, enabling properties to increase group business demand through targeted advertising and improve conversion through proprietary demand management and business intelligence solutions. Cvent solutions optimize the entire event management value chain and have enabled clients around the world to manage hundreds of thousands of meetings and events. For more information, please visit Cvent.com/UK or connect with us on Facebook, Twitter or LinkedIn.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu